Abstract
Haploidentical SCT (haplo-SCT) has been considered a therapeutic option in patients with acquired severe aplastic anemia (SAA) failing at least one course of immune suppressive therapy with antithymocyte globulin and lacking an HLA-matched related or unrelated donor. The platforms of both ex vivo T-cell-depleted and unmanipulated grafts have been explored in children and adults. Overall, the primary objective of a stable haploidentical hematopoietic engraftment with a low rate of GVHD is unmet in a significant proportion of patients undergoing haplo-SCT for SAA. Haploidentical transplants for refractory SAA should be performed in a specialist center with major experience in hematopoietic SCT procedures and preferably performed within the framework of a local clinical protocol designed specifically to address the prevention of graft rejection and GVHD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.
Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et alAcute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574–3581.
Reisner Y, Hagin D, Martelli MF . Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011; 118: 6006–6017.
Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397–4406.
Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921–3928.
Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489–500.
Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol 2006; 34: 1746–1752.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–297.
Liu D, Huang X, Liu K, Xu L, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant 2008; 14: 469–477.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257–265.
Luznik L, O’Donnell P, Symons H, Chen AR, Leffell MS, Zahurak M et al. HLA haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
Tuve S, Gayoso J, Scheid C, Radke J, Kiani A, Serrano D et al. Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia 2011; 25: 880–883.
Peccatori J, Clerici D, Forcina A, Bernardi M, Crocchiolo R, Messina C et al. In-vivo T-regs generation by rapamycin-mycophenolate-ATG as a new platform for GVHD prophylaxis in T-cell repleted unmanipulated haploidentical peripheral stem cell transplantation: results in 59 patients. Bone Marrow Transplant 2010; 45 (Suppl 2): O88.
Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061–1070.
Storb R, Thomas ED, Buckner CD, Clift RA, Deeg HJ, Fefer A et al. Marrow transplantation in thirty "untransfused" patients with severe aplastic anemia. Ann Intern Med 1980; 92: 30–36.
Bacigalupo A, Hows J, Gordon-Simith EC, Gluckman E, Van Lint MT, Congiu M et al. Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings. A report of the EBMT Working Party. Bone Marrow Transplant 1988; 3: 531–535.
Wagner JL, Deeg HJ, Seidel K, Anasetti C, Doney K, Sanders J et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. Transplantation 1996; 61: 54–61.
Passweg JR, Perez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006; 37: 641–649.
Vassiliou GS, Webb DK, Pamphilon D, Knapper S, Veys PA . Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol 2001; 114: 701–705.
Tzeng CH, Chen PM, Fan S, Liu JH, Chiou TJ, Hsieh RK . CY/TBI-800 as a pretransplant regimen for allogeneic bone marrow transplantation for severe aplastic anemia using HLA-haploidentical family donors. Bone Marrow Transplant 1996; 18: 273–277.
Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 2012; 47: 1507–1512.
Woodard P, Cunningham JM, Benaim E, Chen X, Hale G, Horwitz E et al. Effective donor lymphohematopoietic reconstitution after haploidentical CD34+-selected hematopoietic stem cell transplantation in children with refractory severe aplastic anemia. Bone Marrow Transplant 2004; 33: 411–418.
Lacerda JF, Martins C, Carmo JA, Lourenco F, Juncal C, Ismail S et al. Haploidentical stem cell transplantation with purified CD34+ cells after a chemotherapy-alone conditioning regimen in heavily transfused severe aplastic anemia. Biol Blood Marrow Transplant 2005; 11: 399–400.
Koh KN, Im HJ, Kim BE, Choi ES, Jang S, Kwon SW et al. Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia. Br J Haematol 2012; 157: 139–142.
Fang B, Li N, Song Y, Li J, Zhao RC, Ma Y . Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant 2009; 13: 499–502.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ciceri, F., Lupo-Stanghellini, M., Korthof, E. et al. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplant 48, 183–185 (2013). https://doi.org/10.1038/bmt.2012.231
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.231
Keywords
This article is cited by
-
Novel conditioning regimen for upfront haploidentical hematopoietic cell transplantation in children with severe aplastic anemia and donor-specific anti-HLA antibodies
Bone Marrow Transplantation (2022)
-
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
Bone Marrow Transplantation (2022)
-
Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT)
Bone Marrow Transplantation (2021)
-
Combination of haploidentical haematopoietic stem cell transplantation with an unrelated cord-blood unit in patients with severe aplastic anemia: a report of 146 cases
Bone Marrow Transplantation (2020)
-
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
Bone Marrow Transplantation (2019)